1. Introduction {#sec1}
===============

*β*-thalassemias are heterogeneous autosomal recessive hereditary anemia characterized by reduced or absent *β*-globin chain synthesis \[[@B1]\]. Iron overloading is frequently observed in *β*-thalassemia major patients with transfusion therapy \[[@B2]\]. Excessive iron can cause multiple organ damage when deposited in the liver, spleen, pancreas, heart, kidney, skin, pituitary, and other organs \[[@B3]\]. The complications related to iron overloading in patients with transfusion include myocardiopathy, congestive heart failure, liver cirrhosis, arthritis, endocrine disorders such as diabetes, and other diseases. In recent years, the prevalence of abnormal glucose metabolism in *β*-thalassemia major has gradually increased, which may be linked to increased life expectancy in patients with *β*-thalassemia major and growing concern about the combination of thalassemia with diabetes \[[@B4], [@B5]\]. However, according to previously published studies, the prevalence of abnormal glucose metabolism in *β*-thalassemia major was controversial. Hence, this study was conducted to perform a meta-analysis to assess the pooled prevalence of abnormal glucose metabolism in *β*-thalassemia major based on published studies.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

We aimed to search all published studies reporting abnormal glucose metabolism in *β*-thalassemia major patients. Due to the language limitations of the authors, this study only includes English and Chinese publications. To minimize bias, the study region was not being restricted. The search databases included PubMed, ScienceDirect, Springerlink, Ovid, Web of Science, MEDLINE, Wanfang database, and Chinese National Knowledge Internet (CNKI). The publication date was restricted to before June 2018. The present analysis complied with Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. The search strategies in our analysis were as follows:(\#1) diabetes OR impaired glucose tolerance OR impaired fasting glucose(\#2) (*β* AND thalassemia) OR thalassemia OR Mediterranean anemia(\#3) (\#1) and (\#2)

To ensure a comprehensive analysis and minimize selection bias, all references of the included studies were manually retrieved and analyzed. All research and analysis procedures were conducted by two independent authors. Ambiguity in the analysis was verified by referring to the original paper.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The main inclusion criteria for our study were as follows. (i) Patients with *β*-thalassemia major were included if they fulfilled the clinical diagnostic criteria. (ii) All the patients were on regular blood transfusion. (iii) Only original research mentioning abnormal glucose metabolism which included diabetes mellitus (DM), impaired fasting glucose (IFG), or impaired glucose tolerance (IGT) was included. (iv) The diagnostic criteria of diabetes are based on WHO classification. However, several studies did not straightforwardly mention the word "WHO," while the contents of diagnosis criteria in paper were in accordance with WHO. In this case, these papers also have been included in our analysis. (v) The results of the research were presented as calculated data that could be used to calculate the prevalence of different types of abnormal glucose metabolism. The exclusion criteria were as follows: (i) abnormal glucose metabolism was not well classified, in which data of DM, IGT, IFG, or other endocrine disorders cannot be independently extracted from original study; (ii) the data were reported in non-transfusion-dependent thalassemia patients; (iii) there were duplicate data or duplicate publications; (iv) the data could not be used to calculate the prevalence of abnormal glucose metabolism; (v) there was any type of commentaries, including systematic reviews, invited reviews, letters, response to editors, and conference abstracts; (vi) there were papers that were not peer-reviewed.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

Two authors independently selected trials and extracted information on design, selection criteria, numbers or prevalence of abnormal glucose metabolism in *β*-thalassemia major, and baseline assessments and quality assessment from each included study. Disagreements were resolved by discussion with other team members or contact with the original investigators who were all sent emails with requests for the exact data. For missing data that we could not obtain from the primary investigators, estimated values based on the Cochrane Handbook were used in our analysis. The methodological quality of each included study was assessed under the standard of previously published recommendations for observational studies. The checklist for assessing key terms was as follows: data collection method, potential bias of result, discussion of possible confounders, objectives of the research, baseline of patients, and statistical data. The total score was five. Any study with a score less than or equal to four was excluded as low quality.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The meta-analysis was conducted using STATA software version 12.0 (STATA, College Station, TX, USA). We estimated prevalence with 95% confidence intervals for each study via OpenEpi software online, which is available at <http://www.openepi.com/OE2.3/Menu/OpenEpiMenu.htm>. Results from the "Wald (Normal Approximation)" method was used if np\> 5 or n(1-p)\> 5, where n represents the total number and p is the prevalence in the group. Otherwise (np≤5 or n(1-p)≤5), the Mid-P of the exact estimation method was selected. Heterogeneity was assessed using the chi-square and I^2^ statistics and considered significant at p values \<0.05 for chi-square and \>50% for I^2^. If I^2^ \>50%, we conducted a sensitivity analysis to determine the reasons for heterogeneity. Due to the heterogeneity of unit of measurement, the difference of serum ferritin level between abnormal glucose metabolism group and normal glucose metabolism group was calculated as standard mean difference (SMD). When a significant Q-test with P\<0.05 or I^2^\>50% indicated evidence of heterogeneity, the random-effects model was performed. Otherwise, the fixed-effects model was implemented. In cases of heterogeneity, we applied the random-effects model instead of the fixed-effects model because the former includes both within-study variance and between-study sampling error in the assessment of the uncertainty of the results of a meta-analysis. The 95% confidence interval (CI) of each prevalence was calculated to identify the study outcome variation. An outcome measure is considered statistically significant when the 95% CI excludes zero. Missing data were sought from study authors; for data that were not obtainable, values were estimated using methods based on the prevalence of cases of abnormal glucose metabolism in *β*-thalassemia major. Egger\'s line regression and Begg\'s funnel plot were used to evaluate potential publication bias among the included studies. In addition, sensitive analyses and metaregression analysis were conducted to discuss the heterogeneity by publication year.

3. Results {#sec3}
==========

We searched for abnormal glucose metabolism and *β*-thalassemia major in PubMed, Ovid, CNKI, Wanfang Database, Embase, and Web of Science and obtained 1249 items. Of these studies, we determined that various studies were useless because they examined other diseases, deficiency with prevalence or interventions, and so on. Further screening selected 458 items suitable for reading of abstracts. Two studies \[[@B36], [@B41]\] were excluded due to the duplicated publication. Finally, of 51 full-text articles, only 42 studies were included in this meta-analysis \[[@B2]--[@B5], [@B6]--[@B45]\]. In addition, two studies were identified from reference lists \[[@B46], [@B47]\]. A total of 16605 cases diagnosed as *β*-thalassemia major were included in our study. The publication year ranged from 1994 to 2018. The selection flow chart is shown in [Figure 1](#fig1){ref-type="fig"}. Of the included studies, seven studies \[[@B28], [@B31], [@B32], [@B34], [@B38], [@B39], [@B43]\] were from Italy; seven studies \[[@B12], [@B14], [@B16], [@B18], [@B19], [@B29], [@B42]\] were from Iran; five studies \[[@B15], [@B17], [@B25], [@B44], [@B45]\] were from Egypt; five studies \[[@B4], [@B6], [@B20], [@B21], [@B33]\] were from the China region, including the mainland \[[@B20]\], Hong Kong \[[@B21]\], and Taiwan \[[@B4], [@B6], [@B33]\]; three studies \[[@B9], [@B10], [@B30]\] were from India; two studies \[[@B40], [@B47]\] were from Arabia; one study \[[@B35]\] was from Germany. The other studies were from Australia \[[@B24]\], Brazil \[[@B3]\], France \[[@B7]\], Lebanon \[[@B40]\], Oman \[[@B13]\], Turkey \[[@B23], [@B37]\], the United Kingdom \[[@B46]\], and the United States of America \[[@B2]\]. Eight studies \[[@B41], [@B12], [@B13], [@B17], [@B25], [@B27], [@B33], [@B38]\] reported the age at first diagnosis of abnormal glucose metabolism. 20 studies \[[@B2], [@B3], [@B7], [@B9], [@B10], [@B12], [@B13], [@B15], [@B17], [@B19]--[@B23], [@B25], [@B27], [@B33], [@B37], [@B40], [@B45]\] reported the serum ferritin level in *β*-thalassemia major patients. Baseline characteristics are listed in [Table 1](#tab1){ref-type="table"}. As one of the most important indicators of endocrinopathy in *β*-thalassemia major, association between the serum ferritin levels and abnormal glucose metabolism was also determined based on 20 studies \[[@B2], [@B3], [@B7], [@B9], [@B10], [@B12], [@B13], [@B15], [@B17], [@B19]--[@B23], [@B25], [@B27], [@B33], [@B37], [@B40], [@B45]\]. When compared to normal glucose metabolism group, the mean serum ferritin level in abnormal glucose metabolism significant elevated (SMD=1.40, 95% CI: 0.44-2.36; Z=2.85, p=0.004).

3.1. Prevalence of DM in *β*-Thalassemia Major {#sec3.1}
----------------------------------------------

A total of 35 studies were included which assessed diabetes mellitus. The publication year ranged from 1994 to 2018. The prevalence of original diabetes mellitus patients ranged from 0.00% to 26.67%. The meta-analysis revealed that the prevalence of diabetes mellitus in *β*-thalassemia major was 6.54% (95% CI: 5.30%-7.78%). A Forest plot is shown in [Figure 2](#fig2){ref-type="fig"}. In a subgroup analysis, the prevalence in the Mediterranean Coast was 5.36% (95% CI: 3.95%-6.77%). Nevertheless, the highest prevalence region was Oceania, with one study included (prevalence= 18.18%, 95% CI: 6.78%-29.58%) \[[@B24]\]. In order to avoid selection bias, regions with less than five studies were excluded \[[@B2], [@B7], [@B24]\]. The corrected subgroup study revealed that the highest-prevalence region was the Middle East (prevalence= 7.90%, 95% CI: 5.75%-10.05%). The subgroup analysis Forest plot is shown in [Figure 2](#fig2){ref-type="fig"}, with supporting data in [Table 2](#tab2){ref-type="table"}.

3.2. Implication of Study Year for the Prevalence of DM in *β*-Thalassemia Major {#sec3.2}
--------------------------------------------------------------------------------

To assess the implication of study publication year for the prevalence of DM in *β*-thalassemia major, we analyzed the studies by time series. The lowest average prevalence was 2.39% (95% CI: 0.00%-4.93%) in 2018 reported by Gomber S \[[@B30]\] and Teawtrakul N \[[@B5]\], and the highest average prevalence was 11.36% (95% CI: 4.29%-23.40%) in 1999 reported by Labropoulou-Karatza C \[[@B22]\]. An accumulated meta-analysis for the prevalence of DM in *β*-thalassemia major was also conducted to assess the implication of publication year. The prevalence of DM was gradually increasing during the last 20 years, except in studies reported by Borgna-Pignatti C \[[@B38], [@B39]\], Kurtoglu AU \[[@B23]\], and Al-Akhras A \[[@B45]\] ([Figure 3](#fig3){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}).

3.3. Prevalence of IFG in *β*-Thalassemia Major {#sec3.3}
-----------------------------------------------

Seven studies \[[@B10], [@B12], [@B16], [@B20], [@B30], [@B32], [@B44]\] examined impaired fasting glucose. The results of the analysis showed that the prevalence of IFG in *β*-thalassemia major was 17.21% (95% CI: 8.43%-26.00%). In a subgroup analysis, the prevalence of IFG in the Mediterranean Coast was 6.52% (95% CI: 5.74%-7.30%). The highest-prevalence region was the Middle East (prevalence= 27.88%, 95% CI: 18.50%-37.26%). The subgroup analysis Forest plot is shown in [Figure 4(a)](#fig4){ref-type="fig"}, with supporting data in [Table 2](#tab2){ref-type="table"}.

3.4. Prevalence of IGT in *β*-Thalassemia Major {#sec3.4}
-----------------------------------------------

Impaired glucose tolerance was inconsistently mentioned, and twelve studies were reported \[[@B11], [@B12], [@B17], [@B23], [@B25]--[@B27], [@B30], [@B33], [@B35], [@B44], [@B47]\]. The results of the analysis showed that the prevalence of IGT in *β*-thalassemia major was 12.46% (95% CI: 5.98%-18.94%). In a subgroup analysis, the region with the highest prevalence of IGT was the Mediterranean Coast (prevalence= 15.16%, 95% CI: 3.56%-26.76%). The subgroup analysis Forest plot is shown in [Figure 4(b)](#fig4){ref-type="fig"}, with supporting data in [Table 2](#tab2){ref-type="table"}.

3.5. Prevalence of Other Endocrine Disorders in *β*-Thalassemia Major {#sec3.5}
---------------------------------------------------------------------

Eleven studies mentioned other endocrine disorders in *β*-thalassemia major. The main types were hypogonadotropic hypogonadism, hypothyroidism, and hypoparathyroidism. The results of the analysis showed that the prevalence of other endocrine disorders in *β*-thalassemia major was 43.92% (95% CI: 37.94%-49.89%). In a subgroup analysis, the region with the highest prevalence of other endocrine disorders was Europe (prevalence= 65.98%, 95% CI: 56.61%-75.35%), as shown in [Table 2](#tab2){ref-type="table"}.

3.6. Sensitivity Analysis and Publication Bias Assessment {#sec3.6}
---------------------------------------------------------

Sensitivity analysis was performed to evaluate the effects of the methodological quality of each trial on the pooled results. The number of cases in Arrigo T \[[@B43]\], Suvarna J \[[@B9]\], and Mula-Abed WA \[[@B13]\] was less than 30. The studies mentioned above were excluded. The sensitivity analysis showed that the pooled results were robust (prevalence=6.53%, 95% CI: 5.28%-7.79%). The publication bias for diabetes mellitus was detected with funnel plots ([Figure 5(a)](#fig5){ref-type="fig"}) and Egger\'s linear regression ([Figure 5(b)](#fig5){ref-type="fig"}). The shapes of the funnel plots and the linear regression showed no obvious asymmetry, indicating the absence of significant heterogeneity between these selected studies, and the pooled results were not influenced by publication bias.

4. Discussion {#sec4}
=============

Thalassemia is common in the Middle East and Southeast Asia; it is an autosomal recessive hereditary disorder that is caused by various mutations or, rarely, deletions of *β*-globin gene on chromosome 11. The mutations lead to reduced or absent synthesis of the globin chain of hemoglobin, which causes imbalance between the alpha and non-alpha globin chains, therefore resulting in hemolysis for increasing of erythrocyte fragility \[[@B34]\]. Thalassemia has long-term extravascular hemolysis which increases iron absorption in the intestinal tract and decreases the bioavailability of iron. This phenomenon coupled with long-term multiple blood transfusions could lead to iron overload and increase the amount of iron ions \[[@B29], [@B30]\]. The most frequent endocrine disorders were abnormal glucose metabolism, hypogonadotropic hypogonadism, hypothyroidism, and hypoparathyroidism. Patients with thalassemia can exhibit pancreatic tissue and multiple organ dysfunctions. In a series of chronic malignant cycles, patients can develop type 1 diabetes caused by insufficient insulin secretion or type 2 diabetes caused by insulin resistance \[[@B48]\].

At present, bone marrow transplantation is the only available curative option for thalassemia major; due to the graft-versus-host disease and a lack of immunologically matched donors, the main treatment remains traditional long-term blood transfusion and Iron chelation therapy to maintain normal hemoglobin concentrations in the body. In addition, splenectomy is a treatment in thalassemia major with an increased blood requirement, hypersplenism, and symptomatic splenomegaly. These measures have dramatically improved the quality of life for patients with *β*-thalassemia major. But excessive iron deposition is also found in the pancreas, which leads to abnormal glucose metabolism \[[@B14], [@B30]\]. The pathogenesis of abnormal glucose metabolism may include the following aspects: (i) destruction of islet cells caused by excessive iron deposition, which results in insufficient insulin synthesis; (ii) excessive fatty acid oxidation induced by iron accumulation, with a decrease in the body\'s glycogen utilization rate; and (iii) reduction of hepatic capacity to uptake insulin caused by liver function damage \[[@B31], [@B32]\].

The results of the present study confirmed that the prevalence of diabetes mellitus, impaired fasting glucose, and impaired glucose tolerances in *β*-thalassemia major was 6.54%, 17.21%, and 12.46%, respectively. The results of the present study confirmed the fact that prevalence of abnormal glucose metabolism was gradually increasing during the last 20 years. There were no significant correlations between publication quality and the prevalence of DM in the publication bias or sensitivity analysis. Further analyses showed that the region with the highest prevalence of diabetes mellitus and impaired fasting glucose was the Middle East (7.90% and 27.88%, resp.). However, the region with the highest prevalence of IGT was the Mediterranean Coast (15.16%).

In previous reports, the prevalence of DM was reported to vary between 0.00% \[[@B9]\] and 26.67% \[[@B13]\]. This significantly wide interval may reflect differences in diagnostic criteria. The 95% confidence interval of diabetes mellitus in the present study is smaller than those in previous reports. This discrepancy may be due to the large number of cases included in our study compared to previous reports, which ranged from 15 to 3817 cases.

Moreover, we also found that 43.92% of *β*-thalassemia major patients were diagnosed with hypogonadotropic hypogonadism, hypothyroidism, and hypoparathyroidism. We could not evaluate the accuracy of the diagnosis of these endocrine disorders, which was a limitation of the original studies. Hence, we cannot comment on these diseases.

However, there were limitations in this analysis. First, significant heterogeneity was detected in the pooled analyses of prevalence. Although subgroup analyses with the addition of different regions were performed, the heterogeneity was not significantly reduced. This heterogeneity may be due to differences in the number of cases or basic characteristics. Second, there were insufficient data to conduct a complete evaluation of all regions around the world. Third, due to the deficiency of the original data, we could not perform further subgroup analyses by gender, age at diagnosis of endocrinopathy, serum ferritin, or length of blood transfusion. Studies have reported that either age at diagnosis of endocrinopathy or length of blood transfusion may significantly affect glucose metabolism as well as the serum ferritin level \[[@B26]\]. The presented evidence from published papers showed that glucose metabolism or endocrine disorder was also correlated with age or gender \[[@B10], [@B17]\]. These analyses could be considered in further studies based on newly reported data.

In conclusion, we identified the prevalence of abnormal glucose metabolism and other endocrine disorders in *β*-thalassemia major. Corresponding treatment and prevention measurements may be necessary to prevent growth and endocrine problems. These data should be dynamically updated as studies are published.
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###### 

Baseline of included studies.

  No.   Name                    Year   Country         Number   Age                 Age at diagnosis of AGM   Indicators     Quality   Serum ferritin
  ----- ----------------------- ------ --------------- -------- ------------------- ------------------------- -------------- --------- ------------------------
  1     El-Hazmi MA             1994   Arabia          50       \<15                NR                        DM, IGT        5         NR
  2     Group IW                1995   Italy           1861     1-40                NR                        DM, EnD        5         NR
  3     Jensen CE               1997   UK              97       NR                  NR                        EnD            5         NR
  4     Arrigo T                1998   Italy           29       17-42               NR                        DM             5         NR
  5     Borgna-Pignatti C       1998   Italy           1146     NR                  NR                        DM             5         NR
  6     Theodoridis C           1998   Greece          143      7-29                NR                        EnD            4         NR
  7     Labropoulou-Karatza C   1999   Greece          44       16-68(26.8±9)       NR                        DM             5         2819±2450 ng/mL
  8     Cario H                 2000   Germany         157      1-37.5              NR                        IGT            4         NR
  9     Chern JP                2001   Taiwan, China   82       14.8±6.9            17.4(7-24)                IGT            4         3701.3±2530.7 ug/L
  10    Li CK                   2002   HK, China       232      1.4-30.3            NR                        DM             5         5140(468-48490 pmoL/L)
  11    Borgna-Pignatti C       2004   Italy           720      NR                  7m(1d-3y)                 DM             5         NR
  12    Kattamis C              2004   Greece          263      11-14               NR                        DM, IGT        5         NR
  13    De Sanctis V            2004   Italy           3817     NR                  NR                        DM, EnD, IFG   5         NR
  14    Khalifa AS              2004   Egypt           48       10-31(15.9±5.7)     16.8±4.5(11-23)           DM, IGT        5         3648±2219 ug/L
  15    Mowla A                 2004   Iran            98       8-32(15.9±4)        NR                        DM             5         NR
  16    Fung EB                 2006   USA             141      25.8±8.1            NR                        DM             5         3601±2351 ug/L
  17    Suvarna J               2006   India           30       8-15                NR                        DM             5         7623±2381 ng/mL
  18    Mehrvar A               2008   Iran            437      34.7±1.4            NR                        DM             4         NR
  19    Jaruratanasirikul S     2008   Thailand        48       13.6±3.9            11-16                     DM, IGT        4         5206±3291 ug/L
  20    Kidson-Gerber GL        2008   Australia       44       over 18             NR                        DM             4         NR
  21    Gamberini MR            2008   Italy           273      13.9±1.4            NR                        DM             5         NR
  22    Mula-Abed WA            2008   Oman            30       16-32(21.23±3.42)   17.6±2.1(15-21)           DM, EnD        5         5647±3363 ug/L
  23    Najafipour F            2008   Iran            56       15.62±4.44          19.8±4.3                  DM, IGT, IFG   5         2888±948 ug/dL
  24    Thuret I                2010   France          215      0.6-61.2            NR                        DM             5         1240(89-7893) ng/mL
  25    Farmaki K               2011   Greece          15       20-45(35±4.5)       NR                        IGT, EnD       4         NR
  26    Bazrgar M               2011   Iran            555      13.8±5.4            NR                        DM             5         NR
  27    Lobo C                  2011   Brazil          960      28.5±19.8           NR                        EnD            5         2000(405-15874) mcg/L
  28    Kurtoglu AU             2012   Turkey          70       18.66±6.48          NR                        DM, IGT        5         2350±450 ng/mL
  29    Belhoul KM              2013   Arab            382      15.4±7.6            18±3.7                    DM, EnD        5         2597.2±1976.8 ng/L
  30    Mokhtar GM              2013   Egypt           447      0.9-35(14.2±7.7)    NR                        EnD            5         1817±1399 ng/mL
  31    Canatan D               2013   Turkey          246      15.3±8.6            NR                        DM             5         4297.2±2122.5 ng/mL
  32    Mohseni F               2014   Iran            30       5-19(14±4.4)        NR                        IFG            5         NR
  33    Casale M                2014   Italy           86       5-49(23.06±12.6)    NR                        DM             5         NR
  34    Gozashti MH             2014   Iran            300      NR                  NR                        EnD            5         NR
  35    Metwalley KA            2014   Egypt           60       6-18                15.6±1.2                  DM, IGT        5         3011±2101 mg/L
  36    Chen YG                 2015   Taiwan, China   1537     38.2±14.1           NR                        DM             5         NR
  37    Al-Akhras A             2016   Egypt           100      12-18(14.2±1.37)    NR                        DM             5         3577.5±1826 mg/L
  38    Sharma R                2016   India           89       13.6±2.5            NR                        DM, EnD, IFG   5         6667±3294 pmoL/L
  39    Altincik A              2016   Egypt           45       12-18(14.2±1.37)    NR                        DM, IGT, IFG   5         NR
  40    Mashhadi MA             2017   Iran            163      17.80±5.27          NR                        DM             5         4563.50±2849.30 ng/mL
  41    Liang Y                 2017   China           267      7.9±0.2             NR                        DM, IFG        5         4476±158 ug/L
  42    Wu HP                   2017   Taiwan, China   454      0.1-48              NR                        DM             5         NR
  43    Gomber S                2018   India           67       7.43±4.48           NR                        DM, IGT, IFG   5         NR
  44    Teawtrakul N            2018   Thailand        91       19.5±10             NR                        DM             5         NR

NR: not reported; DM: diabetes mellitus; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; AGM: abnormal glucose metabolism.

###### 

Prevalence of abnormal glucose metabolism and other endocrine disorders in *β*-thalassemia major classified by study region.

  Region                DM      IFG          IGT     EnD                                        
  --------------------- ------- ------------ ------- ------------- ------- ------------ ------- -------------
  Mediterranean coast   5.36    3.95-6.77    6.52    5.74-7.30     15.16   3.56-26.76   39.82   33.55-46.10
  Middle East           7.90    5.75-10.05   27.88   18.50-37.26   7.14    0.13-14.15   36.67   31.22-42.11
  Europe                6.05    2.82-9.28    NR      NR            14.01   8.56-19.45   65.98   56.61-75.35
  America               12.77   7.24-18.31   NR      NR            NR      NR           27.50   24.67-30.32
  Asia                  6.38    2.75-10.01   18.29   5.67-30.91    9.07    4.97-13.16   55.06   44.80-65.32
  Oceania               18.18   6.78-29.58   NR      NR            NR      NR           NR      NR
  Overall               6.54    5.30-7.78    17.21   8.43-26.00    12.46   5.98-18.94   43.92   37.94-49.89

DM: diabetes mellitus; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; EnD: endocrine disorders; P: prevalence; 95% CI: 95% confidence interval; NR: not reported.

###### 

Prevalence of abnormal glucose metabolism and other endocrine disorders in *β*-thalassemia major (%).

  Year   DM                  IFG                  IGT                 EnD
  ------ ------------------- -------------------- ------------------- --------------------
  1994   6.00(0.00-12.96)    NR                   2.00(0.00-6.68)     NR
  1995   5.00(4.01-5.99)     NR                   NR                  49.01(46.74-51.28)
  1997   NR                  NR                   NR                  65.98(56.61-75.35)
  1998   7.09(0.51-13.67)    NR                   NR                  28.67(24.28-33.06)
  1999   11.36(1.81-20.92)   NR                   14.14(9.27-19.01)   NR
  2000   NR                  NR                   14.01(8.57-19.46)   NR
  2001   NR                  NR                   8.54(2.37-14.72)    NR
  2002   8.62(4.99-12.26)    NR                   NR                  NR
  2004   4.01(1.63-6.39)     6.50(5.72-7.28)      18.15(9.99-26.32)   40.57(38.73-42.40)
  2006   6.30(0-18.82)       NR                   NR                  NR
  2008   7.89(4.63-11.14)    28.57(16.84-40.31)   7.65(2.35-12.95)    73.33(57.73-88.94)
  2010   6.05(2.82-9.28)     NR                   NR                  NR
  2011   7.93(5.68-10.19)    NR                   NR                  27.50(24.68-30.33)
  2012   10.39(7.57-13.23)   NR                   7.14(0.91-13.37)    31.94(27.27-36.61)
  2013   3.66(1.26-6.07)     NR                   NR                  44.74(40.14-49.35)
  2014   4.79(1.14-8.44)     26.67(11.06-42.27)   8.33(1.14-15.53)    36.67(31.23-42.12)
  2015   7.03(5.75-8.31)     NR                   NR                  NR
  2016   6.54(1.87-11.22)    11.00(5.63-16.37)    4.44(0-11.03)       55.06(44.81-65.32)
  2017   10.87(0-23.28)      29.96(24.47-35.45)   NR                  NR
  2018   2.30(0-4.93)        11.94(4.08-19.79)    10.45(3.01-17.89)   NR

DM: diabetes mellitus; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; EnD: endocrine disorders; NR: not reported.
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